Clinical trials: Stage IB Melanoma
Melanoma (Skin Cancer)
Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.
1. Primary Objective To evaluate the efficacy and safety of cadonilimab in combination with high-dose recombinant human interferon α1b injection as neoadjuvant therapy in patients with stage III/IV melanoma.
- Trial name
- NCT07586904
- Testing
- Cadonilimab and Recombinant Human Interferon α1b Combination Therapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Xijing Hospital
Stage IB Melanoma, Stage IIA Melanoma
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
This randomized phase III trial studies sargramostim before sentinel lymph node biopsy to see how well it works compared to hypertonic saline before sentinel lymph node biopsy in treating patients with melanoma.
- Conditions
- Stage IB Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma
- Trial name
- NCT01826864
- Testing
- sargramostim, sentinel lymph node biopsy, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma, Non-Small Cell Lung Cancer
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
This study is a dose escalation of GR-MD-02 with the standard therapeutic dose of pembrolizumab in patients with advanced melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02575404
- Testing
- GR-MD-02, Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Providence Health & Services
Metastatic NRAS Melanoma
MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma
Patients with metastatic Neuroblastoma RAS (NRAS) melanoma are currently treated with first line immune checkpoint inhibitors (nivolumab, pembrolizumab).
- Trial name
- CHLOROTRAMMEL (NCT03979651)
- Testing
- Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1), Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2), Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)
- Where
- 5 sites in France
- Volunteers
- 29 people
- Sponsor
- Hospices Civils de Lyon
Malignant Melanoma
A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
The main purpose of this trial is to evaluate the safety, tolerability and adverse event profile of pembrolizumab in subjects who have high risk melanoma before and after their standard of care surgical resection, and to collect…
- Trial name
- NCT02434354
- Testing
- pembrolizumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma
A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
A Phase Ib/IIa, multicentre, open label, dose-escalation study to evaluate the safety, tolerability, and preliminary effectiveness of intratumoural tigilanol tiglate in combination with intravenous pembrolizumab in adult patients…
- Trial name
- NCT04834973
- Testing
- tigilanol tiglate, pembrolizumab
- Where
- 2 sites in Australia
- Volunteers
- 3 people
- Sponsor
- QBiotics Group Limited
Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
This phase I/II trial tests the safety and side effects of LN-144 (Lifileucel) and pembrolizumab in treating patients with stage IIIB-D or stage IV melanoma that has spread to nearby tissue or lymph nodes.
- Conditions
- Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Trial name
- NCT05176470
- Testing
- Cyclophosphamide, Fludarabine, Lifileucel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Richard Wu
Renal Cell Carcinoma, Melanoma
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or…
- Conditions
- Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer
- Trial name
- NCT04074967
- Testing
- Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Dan Zandberg
Advanced Melanoma, Advanced Urothelial Carcinoma
Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma
This study is a multi-center, phase Ia/Ib, open clinical study to evaluate the safety, tolerability and pharmacokinetics of TWP-101 in patients with advanced melanoma and urothelial carcinoma.
- Trial name
- NCT04871334
- Testing
- TWP-101
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Shandong TheraWisdom Biopharma Co., Ltd.
Stages III Skin Melanoma, Stages II Skin Melanoma
Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Melanoma's incidence is increasing worldwide. The efforts made in melanoma screening led to an earlier detection of the primary tumour and a better prognosis, but melanoma remains an aggressive cancer when it comes to its…
- Conditions
- Stages III Skin Melanoma, Stages II Skin Melanoma, Stage IB Skin Melanoma
- Trial name
- NCT01988831
- Testing
- Propranolol hydrochloride
- Where
- Switzerland
- Volunteers
- 450 people
- Sponsor
- University Hospital, Geneva
Metastatic Melanoma, Advanced Melanoma
XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
This is a first-in-human, multi-center, multi-cohort, open-label, phase Ib/II study of XmAb22841 (CTLA-4 X LAG3) administered in combination with XmAb23104 (PD1 X ICOS) in participants with a histologically or cytologically…
- Trial name
- NCT05695898
- Testing
- XmAb22841, XmAb23104
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
This phase Ib/II trial studies the side effects and best dose of propranolol hydrochloride when given together with pembrolizumab and how well they work in treating patients with stage IIIC-IV melanoma that cannot be removed by…
- Trial name
- NCT03384836
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Propranolol Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 47 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
This is a multi-center, open-label, phase Ib/II study. First, the aim of the phase Ib part is to estimate the MTD(s) and/or to identify the recommended phase II dose(s) (RP2D) for the combination of MEK162 and AMG 479…
- Trial name
- NCT01562899
- Testing
- MEK162, AMG 479
- Where
- 9 sites in United States, Australia and 6 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
Uveal Melanoma
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
A phase Ib dose-escalation study of the AEB071 and MEK162 combination in adult patients with confirmed metastatic uveal melanoma.
- Trial name
- NCT01801358
- Testing
- AEB071, MEK162
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 38 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Recurrent Melanoma, Stage IA Skin Melanoma
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
This pilot clinical trial studies intravital microscopy for identifying tumor vessels in patients with stage IA-IV melanoma that is being removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma
- Trial name
- NCT01886235
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Melanoma
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and dabrafenib therapy regimen in patients with BRAFV600 mutant unresectable and/or metastatic cutaneous melanoma resistant to…
- Trial name
- NCT03391050
- Testing
- APR-246, Dabrafenib
- Where
- 3 sites in Belgium
- Volunteers
- 3 people
- Sponsor
- Aprea Therapeutics
Advanced Melanoma
A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.
This study is an open-label, multicenter phase Ib/II study to evaluate the efficacy and safety of LBL-024 monotherapy or combination with toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and…
- Trial name
- NCT07099430
- Testing
- LBL-024 for Injection, Toripalimab Injection
- Where
- 16 sites in China
- Volunteers
- 280 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Melanoma
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
The purpose of the study is to assess the safety and efficacy of BGB324 given together with standard treatment, pembrolizumab or dabrafenib and trametinib, compared to standard treatment alone,
- Trial name
- NCT02872259
- Testing
- BGB324+pembrolizumab, BGB324+dabrafenib and trametinib, pembrolizumab
- Where
- 5 sites in Norway
- Volunteers
- 74 people
- Sponsor
- Haukeland University Hospital
Melanoma
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
The purpose of this study is to see how much of the drug Yervoy can be safely tolerated when it is given to people who are also receiving a drug called Sylatron.
- Trial name
- NCT01496807
- Testing
- Sylatron, Yervoy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Uveal Melanoma
Intermittent Selumetinib for Uveal Melanoma
The purpose of this study is to find out what effects, good and/or bad, intermittent dosing of the drug Selumetinib will have on subjects with uveal melanoma.
- Trial name
- NCT02768766
- Testing
- Selumetinib, 100mg, Selumetinib, 125mg, Selumetinib, 150mg
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Shaheer A. Khan